Sector
PharmaceuticalsOpen
₹1,752.2Prev. Close
₹1,753.8Turnover(Lac.)
₹4,757.63Day's High
₹1,764Day's Low
₹1,742.652 Week's High
₹1,830.9552 Week's Low
₹1,232.1Book Value
₹871.05Face Value
₹1Mkt Cap (₹ Cr.)
49,582.68P/E
28.36EPS
61.81Divi. Yield
0.1430 Aug 2024
12:00 AM
AGM
Announcement Date: 30 Aug, 2024
12 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.
ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.
The reshuffle comes after VS Mani, the company's current chief, announced early retirement; he will officially retire as chief on May 26, 2025 after an eight-year career with the company.
This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.
Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 22,942.4 | 17,849.25 | 16,710.37 | 14,781.29 |
Net Worth | 22,970.62 | 17,877.47 | 16,738.59 | 14,809.51 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 7,567.93 | 6,712.63 | 6,403.23 | 7,989.23 |
yoy growth (%) | 12.74 | 4.83 | -19.85 | 30.64 |
Raw materials | -2,999.45 | -2,665.99 | -2,378.59 | -2,425.49 |
As % of sales | 39.63 | 39.71 | 37.14 | 30.35 |
Employee costs | -1,107.39 | -1,072.32 | -1,021.92 | -914.47 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,869.86 | 1,516.09 | 1,218.82 | 2,789.34 |
Depreciation | -150.81 | -138.53 | -118.2 | -104.93 |
Tax paid | -294.31 | -180.09 | -204.47 | -412.28 |
Working capital | 463.74 | -1,507.52 | -180.36 | 1,492.86 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.74 | 4.83 | -19.85 | 30.64 |
Op profit growth | 44.93 | -3.21 | -53.51 | 64.2 |
EBIT growth | 20.49 | 25.73 | -52.08 | 65.02 |
Net profit growth | 21.77 | 33.53 | -52.61 | 44.21 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 13,145.84 | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 |
Other Operating Income | 175.9 | 177.64 | 151.3 | 130.71 | 137.9 |
Other Income | 113.72 | 1,237.32 | 755.86 | 166.67 | 94.76 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,675.7 | 93.94 | 4,02,320.49 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,809.5 | 81.86 | 1,80,822.6 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,505.9 | 25.26 | 1,21,584.26 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,408.2 | 60.56 | 1,15,394.56 | 474 | 0.94 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.3 | 20.03 | 1,07,135.26 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Glenn Saldanha
Executive Director (Corporate)
Cheryl Pinto
Non Executive Director
B E Saldanha
Independent Non Exe. Director
Rajesh Desai.
Independent Non Exe. Director
Sona Saira Ramasastry
Independent Non Exe. Director
Dipankar Bhattacharjee
Independent Non Exe. Director
V R Iyer
Additional Director
Pradeep Kumar Sinha
Additional Director & WTD & ED
Anurag Mantri
B/2 Mahalaxmi Chambers,
22 Bhulabhai Desai Road,
Maharashtra - 400026
Tel: 91-22-40189999
Website: http://www.glenmarkpharma.com
Email: complianceofficer@glenmarkpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological enti...
Read More
Reports by Glenmark Pharmaceuticals Ltd
What is the Glenmark Pharmaceuticals Ltd share price today?
What is the Market Cap of Glenmark Pharmaceuticals Ltd?
What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?
What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?
What is the CAGR of Glenmark Pharmaceuticals Ltd?
What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
